Amarin Corp Plc (AMRN)

[Tatsumaki]

Amarin had the same playing field that everyone else in the industry gets. They had 5 years exclusivity + 30 months legal stay pending the lawsuit on their product. That is 7.5 years of guaranteed competition free sales. They rolled out Reduce It in year 7. Then fumbled the patent lawsuit.

Face it, the issue here isnt the skinny label. Amarin seriously mis-played the game. Everyone else has figured out how to maximize their products revenue potential in the existing regulatory framework. Expecting Congress to change a popular "This makes poor grandma's drugs affordable for her" isnt realistic. Most people think it's working well for the consumer. Well over 80% of Rx in the country are generic.

Drug development and Innovation is stimulated by exclusivity timelines. The US is maybe a little light on that by a year or two vs the EU or Canada, but not too far off. It just means in the US, pricing is more aggressive because the timeline is shorter. Skinny labels were meant to encourage development of new drugs and not have a BP try to work perpetual exclusivity on their old cash cow by slowly dripping out new indications and populations every few years and not pursuing something new.